Next Article in Journal
Effects of Housing and Environmental Enrichment on Performance, Welfare, and Air Quality in Fattening Pigs
Previous Article in Journal
Genome Imputation for Genome-Wide Association Study of Reproductive Traits in Chinese Duroc, Landrace, and Yorkshire Pigs: Strategy and Validation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Animals
Volume 16
Issue 4
10.3390/ani16040584
animals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Gene Expression and Immunohistochemical Analyses of c-Myc in Canine and Feline Soft Tissue Fibrosarcomas

by
Waseem Al-Jameel
1,*,
Ahmad Al-Saidya
1,
Baidaa Salah
2,
Hana Ismail
1 and
Saevan Al-Mahmood
1
1
Department of Pathology and Poultry Diseases, College of Veterinary Medicine, University of Mosul, Mosul 41002, Iraq
2
Department of Biology, College of Education for Pure Science, University of Mosul, Mosul 41002, Iraq
*
Author to whom correspondence should be addressed.
Animals 2026, 16(4), 584; https://doi.org/10.3390/ani16040584
Submission received: 18 January 2026 / Revised: 6 February 2026 / Accepted: 10 February 2026 / Published: 12 February 2026
(This article belongs to the Section Companion Animals)
Browse Figures
Versions Notes

Simple Summary

Cellular myelocytomatosis (c-Myc) has been recommended as a prognostic marker in soft tissue fibrosarcoma in humans. The aim of our study was to assess the mRNA and protein expression of c-Myc in canine and feline fibrosarcoma samples and correlate their expression to histological grading degrees. The expression of the c-Myc marker was significantly correlated to an increased abnormality of cell appearance in canine and feline fibrosarcoma samples. Additional studies are essential to examine the therapeutic and prognostic role of c-Myc in canine and feline fibrosarcoma.

Abstract

Canine and feline fibrosarcomas are malignant tumors of mesenchymal origin showing histological, molecular, and clinical structures similar to their human equivalent. In human medicine, cellular myelocytomatosis (c-Myc) has already been proposed as a vital gene that regulates aggressive cell growth and is a predictive marker and possible therapeutic target in fibrosarcomas. The goal of this study was to evaluate c-Myc expression in canine and feline fibrosarcomas by gene and protein analyses and correlate its expression to the histological grading system of the examined cancers. Nineteen archival formalin-fixed and paraffin-embedded canine and feline sarcoma samples were recruited. Sixteen of them were determined to be canine and feline fibrosarcomas. The samples consisted of eight cutaneous samples, four eyelid samples, three oral mucosa samples, and one vulva sample. Histopathological examinations were performed to estimate histological type, differentiation, cellularity, and mitotic count. On each sample, immunohistochemical assessment and mRNA expression were performed using an anti-c-Myc antibody and a c-Myc primer. The differences in the immunoreactivity staining values and the relative folds of the c-Myc mRNAs were categorized using already recognized grading criteria and a statistical analysis was performed. Among all the tested canine and feline fibrosarcomas, 75% of the grade II fibrosarcoma cases and all of the grade III fibrosarcoma cases were positive for the c-Myc protein. Furthermore, the relative values of the c-Myc gene were up-regulated in grade III compare to grade I and II fibrosarcomas. The results demonstrated that c-Myc expression was significantly higher in grade III than in grade II and I (p ≤ 0.05) fibrosarcomas regarding protein and gene levels. In summary, this work provides evidence for the high expression of c-Myc in canine and feline fibrosarcomas and proposes a supposed relationship with poor prognoses as determined by grading systems.

1. Introduction

Cancers are common in dogs and cats, with approximately one in every ten cats or dogs experiencing cancer during their lifetime [1]. Fibrosarcomas are highly malignant mesenchymal cancers derived from fibroblasts and connective tissue cells and are commonly observed on skin and subcutaneous tissue [2]. Even though fibrosarcomas happen in all domestic animals, they are more frequently seen in the skin of old cats and dogs [3]. In dogs, skin fibrosarcomas form more than 15% of all cancers [3,4]. The fundamental causes of fibrosarcomas are obscure; it has been suggested that changes in chromosomes 11 and 30, subcutaneous injections, trauma, or inflammation may contribute to cancer development in dogs [3,4,5]. In cats, skin fibrosarcomas are more common than in dogs [2,3]. They are usually seen after routine vaccination with rabies and feline leukemia virus vaccines [6,7].
Fibrosarcomas are constantly aggressive and fast-growing and can invade locally and through fascial planes and metastasize to other locations [2,8]. The metastatic foci are usually in the liver, lung, brain, and bones [9]. In spite of improvements in the field of veterinary medicine, dog and cat skin fibrosarcomas remain diagnostically challenging. Quick detection gives the best therapeutic consequences [10]. There is incomplete knowledge of the genetic processes underpinning soft tissue fibrosarcoma progression in dogs and cats. In human fibrosarcoma, a crucial research area is resolving the epigenetic and genetic causes that play an important role to these cancers, for example, the Myc gene [11]. The Myc proto-oncogenes (l-Myc, n-Myc, and c-Myc,) direct more than 15% of the transcription of expressed genes [12]. Myc’s key downstream mediators influence a huge variety of biological actions, for example, cell proliferation, differentiation, and apoptosis [11,12,13]. In mammals, c-Myc modulates several biological activities that are implicated in the cancer cell proliferation. Dysregulation of c-Myc is implicated in many abnormal conditions, for example, increased cell proliferation, genomic instability, immortalization, metastasis, and angiogenesis [12,14,15].
Normally, c-Myc is situated on chromosome F2 and 13 of cats and dogs, respectively [13]. In normal cells, c-Myc expression is very low because of a lack of a positive signaling pathway [14,15,16]. c-Myc expression has been considered to play a role in many cancers, for example, colorectal cancer [17], breast cancer [18], prostate cancer [19], and cervical cancer [20]. In humans, studies have found that c-Myc is highly expressed in many sarcomas including osteosarcoma, leiomyosarcoma, chondrosarcoma, rhabdomyosarcoma, and liposarcoma and it has been related to aggressiveness and a poor prognosis [20,21,22,23,24]. In human fibrosarcoma, c-Myc has revealed promise as a biomarker. Nevertheless, no reports have been issued concerning c-Myc association with dog and cat fibrosarcoma aggressiveness.
Overexpression of the c-Myc transcription factor is found in the nucleus of cancer cells and is connected to the family of basic helix–loop–helix–leucine zippers [25,26,27]. Using the relationship between immunohistochemistry and gene expression and histological grade of malignancy allows us to update the classification of cancer aggressiveness [28,29,30,31].
Therefore, this study aims to determine the expression of the c-Myc gene and protein in canine and feline soft tissue fibrosarcoma samples and the relationship between this marker and the histological grade of malignancy and to evaluate the probability of c-Myc being a valuable marker for this type of cancer.

2. Materials and Methods

2.1. Case Selection

The archives of the Pathology Department, College of Veterinary Medicine, University of Mosul were reviewed for cases of soft tissue carcinoma and sarcoma in canines and felines between 2012 and 2023. A total of 42 formalin-fixed and paraffin-embedded cancer tissues were included (27 canine and 15 feline samples). All of the cancer tissues were classified by two independent pathologists based on their diagnoses as carcinomas or sarcomas (Table 1). The soft cancers either originated from the skin, eyelid, oral mucosa, eyes, eyelids or vulva. A total of 16 soft tissue fibrosarcoma samples (9 canine and 7 feline) were nominated from among these cases.

2.2. Histopathological Examination

Histological sections (5 µm) from fibrosarcoma paraffin-embedded blocks were cut and stained with haematoxylin and eosin (HE). The canine and feline soft tissue fibrosarcoma samples were reassessed and further illustrated. Histologically, samples were further subclassified into a three-grade system [32,33,34]. According to cancer differentiation, cellularity, mitotic activity, and necrosis, the canine soft tissue fibrosarcomas were graded as grade I (low grade), grade II (intermediate grade) or grade III (high grade) [35]. In addition to these, in feline soft tissue fibrosarcoma, the number of inflammatory cells was considered an important part in the grading system [34]. The grading system was divided as follows: grade I, well-differentiated, low cellularity, low mitoses (0–9 mitoses/10 HPFs) and without necrosis and inflammatory cells; grade II, moderately differentiated and moderate cellularity, moderate mitoses (10–19 mitoses/10 HPFs) and with necrosis and inflammatory cells; grade III, poorly differentiated and high cellularity, high mitoses (more than 19 mitoses/10 HPFs), and high necrotic area and inflammatory cells. The slides were assessed and image analysis was performed using an Olympus microscope (Olympus, Tokyo, Japan) with a digital Omax image camera (Omax, Ningbo, China).

2.3. Immunohistochemical Staining

The slides were deparaffinized using xylene and rehydrated using a decreasing concentrations of alcohol; the peroxidase activity was removed by incubation for 15 min in 0.3% H2O2 in methanol. Then the slides were put in a citrate buffer of pH 6.00 and were microwave heated for 10 min. After washing in PBS, pH 7.4, the nonspecific proteins were blocked with 20% normal goat serum (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in PBS. A polyclonal mouse anti-c-Myc primary antibody (Elabscience, Houston, TX, USA) dilution at 1:100 in PBS was placed overnight in a cold room. After washing with PBS, the slides were incubated in a rabbit anti-mouse secondary antibody (Elabscience, Houston, TX, USA) for 30 min diluted in 1:100 PBS. After washing, the sections were sensed with an avidin–biotin complex and then counter-stained with a hematoxylin solution for 1 min, washed, dehydrated, and cover-slipped. For the negative control, tissues were similarly preserved except that normal non-immune serum replaced the c-Myc antibody. Sections of human breast cancer (invasive ductal carcinoma) were used as positive control tissue [36]. The slides were observed using an Olympus microscope (Japan) with a digital Omax image camera (Omax, China). Ten fields (40×) from each cases were blindly assessed by two pathologists and each photo was expounded with (ImageJ Fiji/2.14.0, USA) to quantify c-Myc expression.

2.4. Immunohistochemical Assessment

C-Myc immunoreactivity was determined by a scoring system dependent on the staining intensity and positive cell percentage. The intensity staining was estimated as follows: (0) no staining; (1) weak staining; (2) moderate staining; (3) strong staining [37,38]. The positive cell score was evaluated as follows: negative (0); 1–25% immunopositive cells (1); 26–50% immunopositive cells (2); 51–75% immunopositive cells (3); ≥76–100% immunopositive cells (4) [37,39]. The end product was measured as the multiplication of the positive cell score and the staining intensity score.

2.5. Quantitative RT-PCR

In accordance with the histopathology results found, nine canine soft tissue fibrosarcomas (two from grade I, three from grade II, and four from grade III) and seven feline soft tissue fibrosarcomas (two from grade I, two from grade II, and three from grade III) were used for quantitation of the c-Myc gene. The total RNAs were collected from paraffin-embedded tissues using the FFPE RNA Kit (AmoyDx, Xiamen, China). The primers used for the c-Myc gene in the canine fibrosarcomas were as follows: forward primer, 5′-CCGTAACTCAAGATCGCCCC; reverse primer, 5′-CGCTCCACATGCAGTCCT and in the feline fibrosarcomas they were as follows: forward primer, 5′-TGGCTTGAAGGACACTGTTG; reverse primer, 5′-TGTTTCAACTGTTCTCGCCG, [40]. The integrity and quality of the mRNA was assessed using Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA). Using reverse transcriptase, the mRNAs were transformed into cDNA. The RT-PCR mixtures for c-Myc and β actin were constructed with SYBR Green master mix, cDNAs, forward primer, reverse primer, and nuclease water. The mixture was put in a real-time PCR thermocycler machine. The differences in the relative folds of the c-Myc mRNAs between the grade I, II, and III soft tissue fibrosarcomas were measured in relation to the negative control (skin) and positive control (human breast adenocarcinoma).

2.6. Statistical Analysis

Statistical analysis was performed using the GraphPad software/10.6.1. The c-Myc immunoreactivity data were evaluated using the Mann–Whitney U test to estimate the differences between the grade I, II, and III soft tissue fibrosarcoma groups. A high significance was attributed when p < 0.001, while significance was attributed when p < 0.05. The relative mRNA values in the grade I, II, and III soft tissue fibrosarcoma samples were calculated as the mean of the three groups. The data were analyzed using a one-way ANOVA test in Microsoft Excel. The statistical significance level was set at a p value of <0.05.

3. Results

3.1. Analytical Details for Cancer Cases

An overall of 42 soft tissue malignant cases (27 canine and 15 feline) were found in the archives of the Department of Pathology, College of Veterinary Medicine. From all canine and feline malignant cases, carcinoma represented 55% (23/42) and sarcoma represented 45% (19/42). The histological types of fibrosarcoma percentage was 84% (16/19) from all sarcoma types. The ratio of canine fibrosarcomas to feline fibrosarcomas was approximately the same. At diagnosis, the mean ages of the dogs and cats were 12.5  ±  3.3 years and 10.4  ±  3.1 years, respectively. The canine and feline soft tissue fibrosarcomas most often affected the skin, in approximately 50% of all cases. The skin fibrosarcomas happened at the sites usually used for injections or vaccinations.

3.2. Histopathological Analysis of Fibrosarcoma

The histopathological results of the assessment consistent with the considerations stated earlier are summarized in (Table 2). A total of 16 samples diagnosed as canine and feline fibrosarcoma were investigated. The canine fibrosarcomas have been categorized into three grades: two were grade I (22%), three were grade II (33%), and four were grade III (45%). Grade I fibrosarcoma showed well-differentiated cancer cells within high collagen stroma, low cellularity, and minor atypia. Mitoses were rarely detected. Necrosis was not obvious (Figure 1a,b). Whereas, in grade II fibrosarcoma, cellularity and cellular atypia were increased with low interstitial collagen and some areas of necrosis (Figure 1c,d). However, the grade III fibrosarcoma had an abundance of cellularity, reduced collagen production, numerous atypical mitoses, high necrosis, and immature blood vessels (Figure 1e,f). The feline fibrosarcomas were categorized as grade I in 28.5% of cases, as grade II in 28.5% of cases and as grade III in 43% of cases. Four (47%) of the feline fibrosarcomas in this study displayed some or many spindle-shaped cells with some or many collagen fibers, an absence or low amount of mitoses, negative to moderate necrosis, and negative to mild lymphocyte infiltration and were graded as grade I or grade II (Figure 2a–d). Three (43%) of the feline fibrosarcomas in this study displayed high cellularity with cellular atypia, a low number of collagen fibers, a high number of mitoses, a large area of necrosis, and high perivascular lymphocytic infiltration and were diagnosed as grade III fibrosarcomas (Figure 2e,f).

3.3. c-Myc Immunoreactivity Evaluation

c-Myc expression was mainly detected in the nucleus of monomorphic spindle-shaped cancer fibroblasts (Figure 3). In canine and feline fibrosarcoma, c-Myc expression in grade I was positive in less than 5% of the cells (Figure 3a,b). However, in grade II canine and feline fibrosarcoma, the positive expression of c-Myc was observed in 87% and 56% of cancer fibroblasts, respectively (Figure 3c,d). Among all of the grade III canine and feline fibrosarcomas, approximately 100% of the cancer cells were positive for c-Myc (Figure 3e,f). The mean intensity staining c-Myc expression values were 25 ± 20.81 and 147.2 ± 57.26 for grade I and grade II canine and feline fibrosarcomas, respectively. The statistical evaluation exhibited a very significant difference between c-Myc expression for the grade I and grade II samples (p < 0.001) (Figure 4). The mean c-Myc expression values for the grade II and grade III canine and feline fibrosarcomas were 147.2 ± 57.26 and 283.33 ± 59.64, respectively. The statistical evaluation revealed a significantly higher expression (p ≤ 0.05) between these two groups (Figure 4). The statistical evaluation showed no significant difference between the grade III fibrosarcomas and the positive control (human breast cancer) in terms of their c-Myc expression.

3.4. Evaluation of c-Myc mRNA Expression

The relative values of the c-Myc mRNAs of 16 different canine and feline fibrosarcoma samples are exposed in Figure 5a. All fibrosarcoma samples exhibited abnormal relative values of c-Myc mRNA compared to normal samples, especially in grades II and III. The relative values of the c-Myc gene were irregularly up-regulated in grade III compare to grade I and II fibrosarcoma, and no clear variance in mRNA values was recognized when grade III fibrosarcoma was compared to breast cancer (positive control). Using a one-way ANOVA test, there is a highly significant correlation between the c-Myc mRNA values and the grade of fibrosarcoma with a p-value of <0.05 (Figure 5b).

4. Discussion

C-Myc has been one of the most common and significant oncogenes in cancer biology since its contribution to many vital processes was discovered [41]. It activates the expression of an unusual number of genes implicated in essential functions, for example, cell proliferation, DNA repair, the cell cycle and apoptosis [42,43]. c-Myc is highly expressed in almost all human cancers, certainly its overregulation leads to a numerous genetic variations, for example, chromosomal translocations and gene amplifications, which are linked with the abnormal proliferation of cancer cells [42,44]. c-Myc stimulates tumorigenicity through increased cell proliferation, permitting cancer cells to duplicate without control, stimulating genes participating in protein synthesis, or the encouragement of glucose consumption [45]. In addition, its overexpression generates cells that stimulate angiogenic factor production, for example, vascular endothelial growth factor, which motivates new blood vessel formation [46]. All these things make c-Myc a vital part of cancer progression, causative not only to cancer growth but also to the worsening of metastases and poor outcomes. In human oncology, the c-Myc oncogene shows an important part in the progression and development of many kinds of sarcoma [47]. In veterinary medicine, little is known about the degree of expression of c-Myc in canine and feline fibrosarcoma and its correlation with the malignancy grade of fibrosarcoma. In our study, we aimed to examine the c-Myc gene and protein expression in canine and feline fibrosarcoma archival samples which were categorized by a histopathological grading system into grades I, II and III.
In the retrospective assessment, dog and cat fibrosarcomas were the most common type of sarcoma cases and of these, the most commonly diagnosed were cancers of the skin. These results verify the findings of others [32,48,49]. In addition, fibrosarcomas were detected in older dogs and cats, which is coherent with previous studies defining the mean age at diagnosis of fibrosarcoma [50]. Actually, fibrosarcomas are malignant tumors, as normally believed. Many reports describe fibrosarcomas as low-grade fibrous masses that appear slow-growing [51,52]. In the current study, most (78% and 72%) of the observed canine and feline fibrosarcomas were grade II or III tumors and a strong relationship was detected between low differentiation, high cellularity, and high mitotic activity and the grade of fibrosarcoma.
The c-Myc protein is a nuclear marker linked to unrestrained cellular proliferation and it accelerates cell cycle passage and decreases several cell cycle checkpoints [24,53]. c-Myc expression take place in cells that are replicating, except in (G0) quiescent cells, forming a suitable marker for evaluating the tumorigenicity rate in many types of cancer [24,53,54]. In this research, we observed that c-Myc immunoreactivity is detected mostly in the nucleus of monomorphic spindle-shaped cancer fibroblasts. A high expression score was found in the grade II and III canine and feline fibrosarcoma samples. An even higher c-Myc expression score was noticed among grade II (75%) and III (100%) canine and feline fibrosarcoma cases in comparison with grade I (5%) cases. These results are in line with human medicine reports that confirmed that c-Myc is usually related to higher histological grades in different cancers and is frequently a marker of poor prognosis [55,56]. Regarding grading of cancer, we detected a significant strong relationship between c-Myc expression and cancer grade. Amongst grade I and grade II canine and feline fibrosarcoma cases, we showed a highly significant difference in c-Myc expression (p ≤ 0.001), while all samples of grade III canine and feline fibrosarcoma indicated high c-Myc expression that was the same as the positive control (human breast cancer) [18,27,39,56]. Our results were consistent with human medicine outcomes [54,57], therefore demonstrating a strong relationship between c-Myc expression and the degree of malignancy as imitated by the grading of canine and feline fibrosarcomas. Since grade is the best parameter generally used to display the stage of fibrosarcoma, the increased level of the c-Myc protein is significantly connected to c-Myc expression as a suitable prognostic marker for determining grade.
To corroborate this, further evaluation was arranged concerning the c-Myc mRNA levels of the canine and feline fibrosarcoma samples to evaluate whether c-Myc mRNAs were differentially expressed between grade I, II, and grade III samples. Our finding exposed that the relative fold values were elevated in all grade III fibrosarcoma samples compared to the levels in the grade I and II samples. Previously, expression of c-Myc in mRNA levels has been stated to be linked to poor prognosis in high-grade human solid cancers such as osteosarcoma, synovial sarcoma, liposarcoma, chondrosarcoma, and leiomyosarcoma [21,58,59]. For this reason, the status of c-Myc offers further prognostic indication in canine and feline fibrosarcoma, commonly representing a high-risk tumor, and may be a possible target for developing therapeutic plans, not only in veterinary medicine but also in human medicine.
As far as we know, this is the first study to examine the role of c-Myc expression in gene and protein levels and correlate it with the severity degree grading system for canine and feline fibrosarcoma. The limitations of this research comprise the small cohort size and the inadequate follow-up time, emphasizing the demand for the assessment of this biomarker in potential multicenter and worldwide examinations

5. Conclusions

These results prove that higher expression of the c-Myc gene and protein can be significantly linked to higher grades of canine and feline soft tissue fibrosarcoma, proposing its possible association to cancer development and progression. Nevertheless, since this paper proves associations instead of the causation of malignancy, additional pathway studies are essential to comprehend and interpret large lists of genes associated to the c-Myc gene. In addition, due to a lack of longitudinal clinical outcomes and clinical follow-up analysis, the current conclusions may not have prognostic significance and should be confirmed in future potential studies.

Author Contributions

Conceptualization, W.A.-J. and S.A.-M.; methodology, A.A.-S. and H.I.; software, B.S.; validation, W.A.-J. and S.A.-M.; formal analysis, A.A.-S.; investigation, H.I. and S.A.-M.; resources, W.A.-J. and S.A.-M.; data curation, S.A.-M.; writing—original draft preparation, W.A.-J.; writing—review and editing, W.A.-J., A.A.-S., B.S. and H.I.; visualization, S.A.-M.; supervision, W.A.-J. and S.A.-M.; project administration, A.A.-S.; funding acquisition, W.A.-J. and S.A.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

In this study, ethical approval was surrendered as all samples used in this retrospective study were archival biopsies.

Informed Consent Statement

Not applicable.

Data Availability Statement

The research data presented in this study are accessible in this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
c-MycCellular Myelocytomatosis
H&EHaematoxylin and Eosin
HPFsHigh-Power Fields
IHCImmunohistochemistry

References

  1. Vascellari, M.; Baioni, E.; Ru, G.; Carminato, A.; Mutinelli, F. Animal tumor registry of two provinces in northern Italy: Incidence of spontaneous tumors in dogs and cats. BMC Vet. Res. 2009, 5, 39. [Google Scholar] [CrossRef] [PubMed]
  2. Vegad, J.L. Neoplasia. In A Text Book of Veterinary General Pathology, 2nd ed.; CBS Publication: New Delhi, India, 2007; pp. 351–352. [Google Scholar]
  3. Goldschmidt, M.H.; Hendrick, M.J. Tumors of the Skin and Soft Tissues. In Tumors in Domestic Animals, 4th ed.; Meuten, D.J., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2002; pp. 45–117. [Google Scholar] [CrossRef]
  4. Subapriya, S.S.; Vairamuthu, S.; Pazhanivel, N.; George, R.S.; Vijayarani, K.; Gokulakrishnan, M. Histopathological and Immunohistochemical Diagnosis of Canine Fibrosarcoma. Int. J. Curr. Microbiol. Appl. Sci. 2018, 7, 1376–1379. [Google Scholar] [CrossRef]
  5. Sargan, D.R.; Milne, B.S.; Hernandez, J.A.; O’Brien, P.C.; Ferguson-Smith, M.A.; Hoather, T.; Dobson, J.M. Chromosome rearrangements in canine fibrosarcomas. J. Hered. 2005, 96, 766–773. [Google Scholar] [CrossRef] [PubMed]
  6. Carminato, A.; Vascellari, M.; Marchioro, W.; Melchiotti, E.; Mutinelli, F. Microchip-associated fibrosarcoma in a cat. Vet. Dermatol. 2011, 22, 565–569. [Google Scholar] [CrossRef]
  7. De Man, M.M.; Ducatelle, R.V. Bilateral subcutaneous fibrosarcomas in a cat following feline parvo-, herpes- and calicivirus vaccination. J. Feline Med. Surg. 2007, 9, 432–434. [Google Scholar] [CrossRef]
  8. Davidson, E.B.; Gregory, C.R.; Kass, P.H. Surgical excision of soft tissue fibrosarcomas in cats. Vet. Surg. 1997, 26, 265–269. [Google Scholar] [CrossRef]
  9. Chase, D.; Bray, J.; Ide, A.; Polton, G. Outcome following removal of canine spindle cell tumours in first opinion practice: 104 cases. J. Small Anim. Pract. 2009, 50, 568–574. [Google Scholar] [CrossRef]
  10. Saini, P.; Jangir, B.L.; Narang, G.; Sharma, R.; Priyanka. Pathomorphological and Immunohistochemical Study of Fibrosarcoma in an Adult Dog: A Case Report. Arch. Curr. Res. Int. 2024, 24, 792–798. [Google Scholar] [CrossRef]
  11. Dhanasekaran, R.; Deutzmann, A.; Mahauad-Fernandez, W.D.; Hansen, A.S.; Gouw, A.M.; Felsher, D.W. The MYC oncogene—The grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 2022, 19, 23–36. [Google Scholar] [CrossRef]
  12. Dang, C.V.; O’Donnell, K.A.; Zeller, K.I.; Nguyen, T.; Osthus, R.C.; Li, F. The c-Myc target gene network. Semin. Cancer Biol. 2006, 16, 253–264. [Google Scholar] [CrossRef]
  13. Meyer, N.; Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 2008, 8, 976–990. [Google Scholar] [CrossRef]
  14. Adams, J.M.; Harris, A.W.; Pinkert, C.A.; Corcoran, L.M.; Alexander, W.S.; Cory, S.; Palmiter, R.D.; Brinster, R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318, 533–538. [Google Scholar] [CrossRef] [PubMed]
  15. Dang, C.V. MYC on the path to cancer. Cell 2012, 149, 22–35. [Google Scholar] [CrossRef] [PubMed]
  16. Hehir, D.J.; McGreal, G.; Kirwan, W.O.; Kealy, W.; Brady, M.P. c-myc oncogene expression: A marker for females at risk of carcinoma. J. Surg. Oncol. 1993, 54, 207–209. [Google Scholar] [CrossRef] [PubMed]
  17. Smith, D.R.; Myint, T.; Goh, H.S. Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br. J. Cancer 1993, 68, 407–413. [Google Scholar] [CrossRef][Green Version]
  18. Gao, F.Y.; Li, X.T.; Xu, K.; Wang, R.T.; Guan, X.X. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun. Signal. 2023, 21, 28. [Google Scholar] [CrossRef]
  19. Dong, H.; Hu, J.; Wang, L.; Qi, M.; Lu, N.; Tan, X.; Yang, M.; Bai, X.; Zhan, X.; Han, B. SOX4 is activated by C-MYC in prostate cancer. Med. Oncol. 2019, 36, 92. [Google Scholar] [CrossRef]
  20. Sagawa, Y.; Nishi, H.; Isaka, K.; Fujito, A.; Takayama, M. The correlation of TERT expression with c-myc expression in cervical cancer. Cancer Lett. 2001, 168, 45–50. [Google Scholar] [CrossRef]
  21. Tsiatis, A.C.; Herceg, M.E.; Keedy, V.L.; Halpern, J.L.; Holt, G.E.; Schwartz, H.S.; Cates, J.M. Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Mod. Pathol. 2009, 22, 1432–1438. [Google Scholar] [CrossRef]
  22. Chen, D.; Zhao, Z.; Huang, Z.; Chen, D.C.; Zhu, X.X.; Wang, Y.Z.; Yan, Y.W.; Tang, S.; Madhavan, S.; Ni, W.; et al. Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018, 6, 11. [Google Scholar] [CrossRef]
  23. Tran, D.; Verma, K.; Ward, K.; Diaz, D.; Kataria, E.; Torabi, A.; Almeida, A.; Malfoy, B.; Stratford, E.W.; Mitchell, D.C.; et al. Functional genomics analysis reveals a MYC signature associated with a poor clinical prognosis in liposarcomas. Am. J. Pathol. 2015, 185, 717–728. [Google Scholar] [CrossRef] [PubMed]
  24. Zhang, J.; Song, N.; Zang, D.; Yu, J.; Li, J.; Di, W.; Guo, R.; Zhao, W.; Wang, H. c-Myc promotes tumor proliferation and anti-apoptosis by repressing p21 in rhabdomyosarcomas. Mol. Med. Rep. 2017, 16, 4089–4094. [Google Scholar] [CrossRef] [PubMed]
  25. Lüscher, B.; Larsson, L.G. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation. Oncogene 1999, 18, 2955–2966. [Google Scholar] [CrossRef] [PubMed]
  26. Macek, P.; Cliff, M.J.; Embrey, K.J.; Holdgate, G.A.; Nissink, J.W.M.; Panova, S.; Waltho, J.P.; Davies, R.A. Myc phosphorylation in its basic helix-loop-helix region destabilizes transient α-helical structures, disrupting Max and DNA binding. J. Biol. Chem. 2018, 293, 9301–9310. [Google Scholar] [CrossRef]
  27. Osgrave, N.; Hill, A.D.; Young, L.S. Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J. Mol. Endocrinol. 2006, 37, 377–390. [Google Scholar] [CrossRef]
  28. Aboushousha, T.; Mamdouh, S.; Hamdy, H.; Helal, N.; Khorshed, F.; Safwat, G.; Seleem, M. Immunohistochemical and Biochemical Expression Patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-Associated Hepatocellular Carcinomas. Asian Pac. J. Cancer Prev. 2018, 19, 219–227. [Google Scholar] [CrossRef]
  29. Arafah, M. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. Turk Patoloji Derg. 2012, 28, 38–43. [Google Scholar] [CrossRef]
  30. Lips, E.H.; Mulder, L.; de Ronde, J.J.; Mandjes, I.A.; Koolen, B.B.; Wessels, L.F.; Rodenhuis, S.; Wesseling, J. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res. Treat. 2013, 140, 63–71. [Google Scholar] [CrossRef]
  31. Rehman, F.; Nagi, A.H.; Hussain, M. Immunohistochemical expression and correlation of mammaglobin with the grading system of breast carcinoma. Indian J. Pathol. Microbiol. 2010, 53, 619–623. [Google Scholar] [CrossRef]
  32. Dobromylskyj, M. Feline Soft Tissue Sarcomas: A Review of the Classification and Histological Grading, with Comparison to Human and Canine. Animals 2022, 12, 2736. [Google Scholar] [CrossRef]
  33. Patterson, J.W.; Tchernev, G.; Chokoeva, A.A.; Wick, M.R. Sclerosing epithelioid fibrosarcoma. Wien. Med. Wochenschr. 2017, 167, 120–123. [Google Scholar] [CrossRef] [PubMed]
  34. Mikiewicz, M.; Paździor-Czapula, K.; Fiedorowicz, J.; Gesek, M.; Otrocka-Domagała, I. Metallothionein expression in feline injection site fibrosarcomas. BMC Vet. Res. 2023, 19, 42. [Google Scholar] [CrossRef] [PubMed]
  35. Vascellari, M.; Melchiotti, E.; Bozza, M.A.; Mutinelli, F. Fibrosarcomas at presumed sites of injection in dogs: Characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. J. Vet. Med. A Physiol. Pathol. Clin. Med. 2003, 50, 286–291. [Google Scholar] [CrossRef] [PubMed]
  36. He, Y.; Liu, Z.; Qiao, C.; Xu, M.; Yu, J.; Li, G. Expression and significance of Wnt signaling components and their target genes in breast carcinoma. Mol. Med. Rep. 2014, 9, 137–143. [Google Scholar] [CrossRef]
  37. Blancato, J.; Singh, B.; Liu, A.; Liao, D.J.; Dickson, R.B. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br. J. Cancer 2004, 90, 1612–1619. [Google Scholar] [CrossRef]
  38. Mahmoud, A.Z.; George, T.I.; Czuchlewski, D.R.; Zhang, Q.Y.; Wilson, C.S.; Sever, C.E.; Bakhirev, A.G.; Zhang, D.; Steidler, N.L.; Reichard, K.K.; et al. Scoring of MYC protein expression in diffuse large B-cell lymphomas: Concordance rate among hematopathologists. Mod. Pathol. 2015, 28, 545–551. [Google Scholar] [CrossRef]
  39. Shi, W.; Xu, X.; Huang, R.; Yu, Q.; Zhang, P.; Xie, S.; Zheng, H.; Lu, R. Plasma C-MYC level manifesting as an indicator in progression of breast cancer. Biomark. Med. 2019, 13, 917–929. [Google Scholar] [CrossRef]
  40. Manzoor, S.; Awan, A.R.; Wajid, A.; Firyal, S.; Tayyab, M.; Mansha, M.; Mahmood, A.K.; Hashmi, A.S.; Wasim, M. c-Myc has Altered Expression in Canine and Feline Tumors. Pakistan J. Zool. 2017, 49, 2147–2152. [Google Scholar] [CrossRef]
  41. Ahmadi, S.E.; Rahimi, S.; Zarandi, B.; Chegeni, R.; Safa, M. Correction to: MYC: A multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J. Hematol. Oncol. 2021, 14, 135. [Google Scholar] [CrossRef]
  42. Stine, Z.E.; Walton, Z.E.; Altman, B.J.; Hsieh, A.L.; Dang, C.V. MYC, Metabolism, and Cancer. Cancer Discov. 2015, 5, 1024–1039. [Google Scholar] [CrossRef]
  43. Scafuro, M.; Capasso, L.; Carafa, V.; Altucci, L.; Nebbioso, A. Gene Transactivation and Transrepression in MYC-Driven Cancers. Int. J. Mol. Sci. 2021, 22, 3458. [Google Scholar] [CrossRef] [PubMed]
  44. Kumari, A.; Folk, W.P.; Sakamuro, D. The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. Genes 2017, 8, 158. [Google Scholar] [CrossRef] [PubMed]
  45. Wahlström, T.; Henriksson, M.A. Impact of MYC in regulation of tumor cell metabolism. Biochim. Biophys. Acta 2015, 1849, 563–569. [Google Scholar] [CrossRef]
  46. Baudino, T.A.; McKay, C.; Pendeville-Samain, H.; Nilsson, J.A.; Maclean, K.H.; White, E.L.; Davis, A.C.; Ihle, J.N.; Cleveland, J.L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002, 16, 2530–2543. [Google Scholar] [CrossRef] [PubMed]
  47. Sias, F.; Zoroddu, S.; Migheli, R.; Bagella, L. Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target. Int. J. Mol. Sci. 2025, 26, 1973. [Google Scholar] [CrossRef]
  48. Misdorp, W.; Cotchin, E.; Hampe, J.F.; Jabara, A.G.; Von Sandersleben, J. Canine malignant mammary tumours. I. Sarcomas. Vet. Pathol. 1971, 8, 99–117. [Google Scholar] [CrossRef]
  49. da Martins, A.M.C.R.P.; Tamaso, E.; Guerra, J.L. Retrospective review and systematic study of mammary tumors in dogs and characteristics of the extracellular matrix. Braz. J. Vet. Res. Anim. Sci. 2002, 9, 38–42. [Google Scholar] [CrossRef]
  50. Frazier, S.A.; Johns, S.M.; Ortega, J.; Zwingenberger, A.L.; Kent, M.S.; Hammond, G.M.; Rodriguez, C.O.; Steffey, M.A.; Skorupski, K.A. Outcome in dogs with surgically resected oral fibrosarcoma (1997–2008). Vet. Comp. Oncol. 2012, 10, 33–43. [Google Scholar] [CrossRef]
  51. Ciekot, P.A.; Powers, B.E.; Withrow, S.J.; Straw, R.C.; Ogilvie, G.K.; LaRue, S.M. Histologically low-grade, yet biologically high-grade, fibrosarcomas of the mandible and maxilla in dogs: 25 cases (1982–1991). J. Am. Vet. Med. Assoc. 1994, 204, 610–615. [Google Scholar] [CrossRef]
  52. Hershey, A.E.; Sorenmo, K.U.; Hendrick, M.J.; Shofer, F.S.; Vail, D.M. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986–1996). J. Am. Vet. Med. Assoc. 2000, 216, 58–61. [Google Scholar] [CrossRef]
  53. Deb-Basu, D.; Karlsson, A.; Li, Q.; Dang, C.V.; Felsher, D.W. MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2. Cell Cycle 2006, 5, 1348–1355. [Google Scholar] [CrossRef]
  54. Melnik, S.; Werth, N.; Boeuf, S.; Hahn, E.M.; Gotterbarm, T.; Anton, M.; Richter, W. Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells. Stem Cell Res. Ther. 2019, 10, 73. [Google Scholar] [CrossRef]
  55. Golijow, C.D.; Abba, M.C.; Mourón, S.A.; Gómez, M.A.; Dulout, F.N. c-myc gene amplification detected in preinvasive intraepithelial cervical lesions. Int. J. Gynecol. Cancer 2001, 11, 462–465. [Google Scholar] [CrossRef]
  56. Green, A.R.; Aleskandarany, M.A.; Agarwal, D.; Elsheikh, S.; Nolan, C.C.; Diez-Rodriguez, M.; Macmillan, R.D.; Ball, G.R.; Caldas, C.; Madhusudan, S.; et al. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br. J. Cancer 2016, 114, 917–928. [Google Scholar] [CrossRef]
  57. Lachman, H.M.; Skoultchi, A.I. Expression of c-myc changes during differentiation of mouse erythroleukaemia cells. Nature 1984, 310, 592–594. [Google Scholar] [CrossRef]
  58. Scionti, I.; Michelacci, F.; Pasello, M.; Hattinger, C.M.; Alberghini, M.; Manara, M.C.; Bacci, G.; Ferrari, S.; Scotlandi, K.; Picci, P.; et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann. Oncol. 2008, 19, 1500–1508. [Google Scholar] [CrossRef]
  59. Barrios, C.; Castresana, J.S.; Kreicbergs, A. Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification. Am. J. Clin. Oncol. 1994, 17, 273–276. [Google Scholar] [CrossRef]
Animals 16 00584 g001
Figure 1. Photomicrographs of the canine soft tissue fibrosarcomas: (a) Grade I fibrosarcoma, spindle-shaped cells organized as an interwoven pattern within minor atypia; (b) grade I fibrosarcoma, high number of collagen stroma and a low number of spindle-shaped cells without mitotic activity; (c) grade II fibrosarcoma, closely packed spindle cells organized as fascicles and few collagen fibers in between cells with some areas of necrosis (arrow); (d) grade II fibrosarcoma, weaved bundles of cancer cells with elongated or oval hyperchromatic nuclei and low mitotic activity (arrows); (e) grade III fibrosarcoma, abundance of cellularity with prominent cellular atypia and increased areas of necrosis (arrows); (f) grade III fibrosarcoma, closely packed cancer cells with pleomorphic nuclei, less collagen in between cells and frequent mitotic activity (arrows). ((a–f) H&E; magnification: (a,c,e) scale bar = 100 µm, ×10; (b,d,f) scale bar = 20 µm, ×40).
Figure 1. Photomicrographs of the canine soft tissue fibrosarcomas: (a) Grade I fibrosarcoma, spindle-shaped cells organized as an interwoven pattern within minor atypia; (b) grade I fibrosarcoma, high number of collagen stroma and a low number of spindle-shaped cells without mitotic activity; (c) grade II fibrosarcoma, closely packed spindle cells organized as fascicles and few collagen fibers in between cells with some areas of necrosis (arrow); (d) grade II fibrosarcoma, weaved bundles of cancer cells with elongated or oval hyperchromatic nuclei and low mitotic activity (arrows); (e) grade III fibrosarcoma, abundance of cellularity with prominent cellular atypia and increased areas of necrosis (arrows); (f) grade III fibrosarcoma, closely packed cancer cells with pleomorphic nuclei, less collagen in between cells and frequent mitotic activity (arrows). ((a–f) H&E; magnification: (a,c,e) scale bar = 100 µm, ×10; (b,d,f) scale bar = 20 µm, ×40).
Animals 16 00584 g001
Animals 16 00584 g002
Figure 2. Photomicrographs of the feline soft tissue fibrosarcomas: (a) Grade I fibrosarcoma, few spindle-shaped cells organized as a whorled pattern with more fibrous and myxoid materials appearing as collagen-rich materials; (b) grade I fibrosarcoma, high collagen, low cellularity without mitotic activity and minimal pleomorphism; (c) grade II fibrosarcoma, many spindle cells with few collagen fibers in between cells surrounded by lymphoplasmacytic inflammation (arrows); (d) grade II fibrosarcoma, pleomorphic cancer cell population with irregular mitotic activity (arrows) surrounded by lymphocytes (arrowheads); (e) grade III fibrosarcoma, abundance of cellularity with prominent cellular atypia and lymphoplasmacytic infiltrates (arrowheads) around the area of necrosis (arrow); (f) grade III fibrosarcoma, closely packed cancer cells with pleomorphic nuclei, less collagen in between cells and frequent mitotic activity (arrows). ((a–f) H&E; magnification: (a,c,e) scale bar = 100 µm, ×10; (b,d,f) scale bar = 20 µm, ×40).
Figure 2. Photomicrographs of the feline soft tissue fibrosarcomas: (a) Grade I fibrosarcoma, few spindle-shaped cells organized as a whorled pattern with more fibrous and myxoid materials appearing as collagen-rich materials; (b) grade I fibrosarcoma, high collagen, low cellularity without mitotic activity and minimal pleomorphism; (c) grade II fibrosarcoma, many spindle cells with few collagen fibers in between cells surrounded by lymphoplasmacytic inflammation (arrows); (d) grade II fibrosarcoma, pleomorphic cancer cell population with irregular mitotic activity (arrows) surrounded by lymphocytes (arrowheads); (e) grade III fibrosarcoma, abundance of cellularity with prominent cellular atypia and lymphoplasmacytic infiltrates (arrowheads) around the area of necrosis (arrow); (f) grade III fibrosarcoma, closely packed cancer cells with pleomorphic nuclei, less collagen in between cells and frequent mitotic activity (arrows). ((a–f) H&E; magnification: (a,c,e) scale bar = 100 µm, ×10; (b,d,f) scale bar = 20 µm, ×40).
Animals 16 00584 g002
Animals 16 00584 g003
Figure 3. Expression of c-Myc in canine (a,c,e) and feline (b,d,f) soft tissue fibrosarcomas: (a) Canine grade I fibrosarcoma, negative c-Myc staining; (c) canine grade II fibrosarcoma, strong nuclear c-Myc staining in more than 85% of cells (arrows); (e) canine grade III fibrosarcoma, very strong nuclear c-Myc staining in almost all of the cells (arrows); (b) feline grade I fibrosarcoma, negative c-Myc staining; (d) feline grade II fibrosarcoma, weak nuclear staining of c-Myc in 56% of cells (arrows); (f) feline grade III fibrosarcoma, strong nuclear staining of c-Myc in almost all of the cells (arrows); (g) negative control in the absence of c-Myc antibody; (h) very strong cytoplasmic and nuclear c-Myc expression in breast cancer (positive control) (black arrows). ((a–h) IHC staining; original magnification: (a–g) ×40, scale bar = 20 µm).
Figure 3. Expression of c-Myc in canine (a,c,e) and feline (b,d,f) soft tissue fibrosarcomas: (a) Canine grade I fibrosarcoma, negative c-Myc staining; (c) canine grade II fibrosarcoma, strong nuclear c-Myc staining in more than 85% of cells (arrows); (e) canine grade III fibrosarcoma, very strong nuclear c-Myc staining in almost all of the cells (arrows); (b) feline grade I fibrosarcoma, negative c-Myc staining; (d) feline grade II fibrosarcoma, weak nuclear staining of c-Myc in 56% of cells (arrows); (f) feline grade III fibrosarcoma, strong nuclear staining of c-Myc in almost all of the cells (arrows); (g) negative control in the absence of c-Myc antibody; (h) very strong cytoplasmic and nuclear c-Myc expression in breast cancer (positive control) (black arrows). ((a–h) IHC staining; original magnification: (a–g) ×40, scale bar = 20 µm).
Animals 16 00584 g003
Animals 16 00584 g004
Figure 4. The mean intensity staining values for c-Myc expression in the evaluated groups. Highly significant difference in expression (p ≤ 0.001) (***) of c-Myc between grade I and grade II canine and feline fibrosarcoma; highly significant difference in expression (p ≤ 0.05) (*) of c-Myc between grade II and grade III canine and feline fibrosarcoma; no significant difference in c-Myc expression between grade III and the positive control (human breast cancer).
Figure 4. The mean intensity staining values for c-Myc expression in the evaluated groups. Highly significant difference in expression (p ≤ 0.001) (***) of c-Myc between grade I and grade II canine and feline fibrosarcoma; highly significant difference in expression (p ≤ 0.05) (*) of c-Myc between grade II and grade III canine and feline fibrosarcoma; no significant difference in c-Myc expression between grade III and the positive control (human breast cancer).
Animals 16 00584 g004
Animals 16 00584 g005
Figure 5. The values and significant association of c-Myc mRNA expression and grade I, II, and III canine and feline fibrosarcomas: (a) The values of the relative levels of the c-Myc mRNAs between grade I, II, and III canine and feline fibrosarcomas (Y axis) in comparison with the case number (X axis). Number 1 is the negative control sample and numbers 6, 7, 9, in grade I, II, and III respectively are the positive breast cancer sample; (b) A significant relationship between c-Myc mRNA expression and grade I, II, and III canine and feline fibrosarcoma using a one-way ANOVA test; significance was determined when p < 0.05.
Figure 5. The values and significant association of c-Myc mRNA expression and grade I, II, and III canine and feline fibrosarcomas: (a) The values of the relative levels of the c-Myc mRNAs between grade I, II, and III canine and feline fibrosarcomas (Y axis) in comparison with the case number (X axis). Number 1 is the negative control sample and numbers 6, 7, 9, in grade I, II, and III respectively are the positive breast cancer sample; (b) A significant relationship between c-Myc mRNA expression and grade I, II, and III canine and feline fibrosarcoma using a one-way ANOVA test; significance was determined when p < 0.05.
Animals 16 00584 g005
Table 1. Formalin-fixed and paraffin-embedded cancer soft samples (42 cases) were initially classified into canine or feline cases by location of cancer and then diagnosed as carcinoma or sarcoma; after that, fibrosarcoma cases were selected by histopathological characterization.
Table 1. Formalin-fixed and paraffin-embedded cancer soft samples (42 cases) were initially classified into canine or feline cases by location of cancer and then diagnosed as carcinoma or sarcoma; after that, fibrosarcoma cases were selected by histopathological characterization.
Type of AnimalPositionDiagnosisSarcoma Categorization
CanineSkinCarcinoma (8); Sarcoma (5)Myxosarcoma (1); Fibrosarcoma (4)
EyelidsCarcinoma (3); Sarcoma (2)Fibrosarcoma (2)
Oral mucosaCarcinoma (2); Sarcoma (2)Fibrosarcoma (2)
EyeCarcinoma (3); Sarcoma (0)----
VulvaCarcinoma (1); Sarcoma (1)Fibrosarcoma (1)
FelineSkinCarcinoma (2); Sarcoma (5)Angiosarcoma (1); Fibrosarcoma (4)
EyelidsCarcinoma (3); Sarcoma (2)Fibrosarcoma (2)
Oral mucosaCarcinoma (1); Sarcoma (2)Unknown (1); Fibrosarcoma (1)
Table 2. Association of the histopathological characteristics in canine and feline soft tissue fibrosarcoma samples.
Table 2. Association of the histopathological characteristics in canine and feline soft tissue fibrosarcoma samples.
AnimalCaseLocation* Differentiation** Cellularity*** Mitotic Activity**** NecrosisFinal Grade
Canine1Skin++M21II
2Skin+++H31III
3Skin+++H32III
4Skin+L10I
5Eyelids++M21II
6Eyelids++M11II
7Oral mucosa+++H32III
8Oral mucosa+++H32III
9Vulva+L10I
CaseLocation* Differentiation** Cellularity*** Mitotic activity**** Necrosis/Inflam. cellsFinal grade
Feline1Skin+++H32III
2Skin++M21II
3Skin+++H31III
4Skin+L10I
5Eyelids+++H32III
6Eyelids++M11II
7Oral mucosa+L10I
* Differentiation: (+++) Poorly differentiated; (++) Moderately differentiated; (+) Well-differentiated; ** Cellularity/field: (L) Low; (M) Moderate; (H) High; *** Mitotic activity: Mitotic cell figures 0–9/10 HPF = (1); 10–19/10 HPF= (2); >19/10 HPF = (3); **** Necrosis: 0 (no necrosis), 1 (<50% necrosis), 2 (>50% necrosis).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Al-Jameel, W.; Al-Saidya, A.; Salah, B.; Ismail, H.; Al-Mahmood, S. Gene Expression and Immunohistochemical Analyses of c-Myc in Canine and Feline Soft Tissue Fibrosarcomas. Animals 2026, 16, 584. https://doi.org/10.3390/ani16040584

AMA Style

Al-Jameel W, Al-Saidya A, Salah B, Ismail H, Al-Mahmood S. Gene Expression and Immunohistochemical Analyses of c-Myc in Canine and Feline Soft Tissue Fibrosarcomas. Animals. 2026; 16(4):584. https://doi.org/10.3390/ani16040584

Chicago/Turabian Style

Al-Jameel, Waseem, Ahmad Al-Saidya, Baidaa Salah, Hana Ismail, and Saevan Al-Mahmood. 2026. "Gene Expression and Immunohistochemical Analyses of c-Myc in Canine and Feline Soft Tissue Fibrosarcomas" Animals 16, no. 4: 584. https://doi.org/10.3390/ani16040584

APA Style

Al-Jameel, W., Al-Saidya, A., Salah, B., Ismail, H., & Al-Mahmood, S. (2026). Gene Expression and Immunohistochemical Analyses of c-Myc in Canine and Feline Soft Tissue Fibrosarcomas. Animals, 16(4), 584. https://doi.org/10.3390/ani16040584

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop